News
Merck KGaA to buy Springworks for $3.9 billion Merck KGaA (OTCPK:MKGAF) is set to acquire SpringWorks Therapeutics (SWTX) for $3.9 billion to enhance its cancer drug business. The acquisition is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback